Jeff D’Agostino, CEO & President

Jeffrey D’Agostino founded 206 Ortho, Inc. in 2011. He is veteran of over 19 years in medical devices/pharmaceuticals including working with Pfizer, Immedica, Integra, Micro Therapeutics, and ev3. For the decade prior to founding 206 Ortho, Jeff gained extensive experience with several successful high growth/early stage medical device companies in neurosurgery and interventional neuroradiology focusing on marketing and sales. He also holds several pending patents related to medical devices.

Jeff’s educational background includes a bachelor’s of science with a major in psychology and a minor in biology. He earned an MBA at Babson College F.W. Olin School of business.

Chris Lin, Advisor

Christopher Lin has spent nearly 20 years advising high-growth companies and their investors with respect to M&A and other strategic transactions.  A corporate lawyer by training, Chris spent 12 years as a partner in the Private Equity and M&A group of a large, international law firm in Chicago, before joining Arthrex as its Deputy General Counsel & Director of Corporate Development.  Chris is currently the Managing Member of Aspect Growth Partners, a corporate development firm that deploys a multi-disciplinary approach in support of strategic business transactions.

Nicholas Pachuda, Advisor

Nicholas Pachuda has 17 years in the Orthopedic industry as an innovation and commercial leader, most recently with J&J/DePuy Synthes. He has a history of successfully creating new ventures or exits with Synthes, Arthrex, and Scient’x Spine. He completed an Orthopedic Trauma Fellowship and has 10 years of clinical practice as a Foot & Ankle Surgeon.

Rick Randall, Advisor

Rick Randall has dedicated the last 30 years of his career developing and commercializing game-changing medical devices into the global healthcare market. Most recently Rick was the President and CEO at OMNI Life Science. Prior to OMNI, Rick served as President & CEO for emerging-growth medical device companies, Medical Compression System, Avantis Medical, Trans1 Inc., Innovasive Devices Inc, and Target Therapeutics Inc. Has has managed commercial enterprises serving a wide range of medical markets including: interventional neurosurgery, orthopedic surgery, orthopedic arthroscopic surgery, minimally invasive spine surgery and gastrointestinal diagnostics.

Rick has created shareholder value through managing companies through three initial public offerings of stock on the NASDAQ Exchange and two strategic acquisitions. Mr. Randall is also co-founder of Conceptus, Inc and Cardima, Inc and has served on the Board of Directors of companies such as Conceptus (Bayer), Salient Surgical (Medtronic), Endocardial Solutions (St. Jude Medical), MicroTherapeutics (Covidien) and Microvention (Terumo).

Art Watterson, Ph.D, Scientific Advisor

Arthur Watterson, Ph.D, is a University of Massachusetts Lowell chemistry professor of 40 years.  He served as chair of the department and has held leadership positions in his field of research including a position as the Director of the Institute for Nano Science and Engineering Technology at UML.  He has been awarded numerous patents, has published over 200 publications and accrued many honors for his teaching. He is a resident of Nashua, NH.

Werner Blank, Scientific Advisor

Werner is a world renowned expert in the field of polymer and coating chemistry. He brings >50 years of experience in designing and synthesizing commercial polymers and catalysts for high performance applications in automotive, aerospace among other industries. Werner has more than 50 patents issued patents, and is well known for developing commercial resins with reduced emissions, increased cure response, and improved mechanical properties.

Charlie Hegedus, Ph.D, Scientific Advisor

Dr. Hegedus brings over 35 years of experience in developing formulations of performance polymers and close industry relationships. He has worked in the Performance Materials Division at Air Products and Chemicals since 1993. Prior to joining Air Products, Hegedus was employed at the Naval Air Development Center where he was Technical Leader of the Protective Coatings Group. Dr. Hegedus holds >25 US patents and has authored over 65 papers and publications. He also serves on a number of national committees.